Original Title: Vemurafenib en combinación con cobimetinib en melanoma avanzado

Authors' recommendations: CONCLUSIONS Moderate quality evidence shows that first line combination therapy with vemurafenib plus cobimetinib in patients with unresectable or metastatic melanoma with BRAF V600 mutation is associated with longer overall survival and disease-free progression as well as a better objective response when compared with vemurafenib as monotherapy. No studies were found comparing this combination with other currently used first-line therapeutic options such as ipilimumab or anti-PD1 antibodies, although evidence from indirect comparisons suggests that there would be no differences in overall survival when compared with antibodies such as nivolumab, pembrolizumab or combined dabrafenib/trametinib. The clinical practice guidelines of the main oncology societies consider the combination among the treatment alternatives for the mentioned population; its use is preferred as first line therapy if a rapid clinical response is needed based on the disease symptoms and/or tumor burden. Furthermore, most public and private health sponsors of high-income countries consider using both drugs in combination for patients with advanced melanoma; in some cases only after reaching a retail price agreement.

Project Status: Completed

Year Published: 2017

URL for published report: https://www.iecs.org.ar/home-ets/

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: Argentina

Organisation Name: Institute for Clinical Effectiveness and Health Policy

Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA

Contact Name: info@iecs.org.ar

Contact Email: info@iecs.org.ar

Copyright: <p>Institute for Clinical Effectiveness and Health Policy (IECS)</p>